Premium
Filgotinib for treating moderate to severe rheumatoid arthritis
Author(s) -
Chaplin Steve
Publication year - 2021
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1920
Subject(s) - medicine , rheumatoid arthritis , antirheumatic drugs , janus kinase , janus kinase inhibitor , nice , antirheumatic agents , tofacitinib , receptor , computer science , programming language
Filgotinib (Jyseleca) is a new oral janus kinase (JAK) inhibitor that has recently been approved by NICE for moderate or severe rheumatoid arthritis after failure of other disease‐modifying antirheumatic drugs (DMARDs). This article discusses its efficacy, side‐effects and place in therapy.